Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study for the effect on blood pressure and heart rate fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor Luseogliflozin in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Trial Profile

Study for the effect on blood pressure and heart rate fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor Luseogliflozin in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luseogliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms LUNA; Luseogliflozin ABPM study
  • Most Recent Events

    • 29 Nov 2021 Status changed from active, no longer recruiting to completed.
    • 29 Jun 2021 Primary endpoint has been met (Changes in average of systolic blood pressure during the night-time section) , according to Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top